Document Classification

Section Type: RESULTS

Text: Fewer patients randomized to sirolimus-eluting stents experienced major adverse cardiac events (12/129 [9. 3 %] vs 40/128 [31. 3 %] ; RR, 0. 30 ; 95 % CI, 0. 15-0. 55 ; P <. 001) mainly because of a reduction in target lesion revascularization (9/129 [7 %] vs 27/128 [21. 1 %] ; RR, 0. 33 ; 95 % CI, 0. 14-0. 70 ; P =. 002) and myocardial infarction (2/129 [1. 6 %] vs 10/129 [7. 8 %] ; RR, 0. 20 ; 95 % CI, 0. 01-0. 93 ; P =. 04).